Cannabinoid Modulation for Neurogenic Lower Urinary Tract Dysfunction in Spinal Cord Injury
University of Wisconsin, Madison
Summary
The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI). Participants will take Epidiolex (purified CBD) for 90 days
Description
This pilot study assesses the feasibility of using 100mg of twice daily cannabidiol (Epidiolex) in adult spinal cord injury with neurogenic lower urinary tract dysfunction following resolution of spinal shock.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * \>18 years of age * History of supra-sacral spinal cord injury of any mechanism * Urinary incontinence with ≥2 episodes of urinary incontinence per day (outside of spinal shock) * Willingness to participate in drug intervention trial * English-speaking (able to provide consent and complete questionnaires) Exclusion Criteria: * History of intravesical Botox * Actively taking \>15 mg of Oxybutynin single dose or equivalent dose of alternative anticholinergic medication for bladder symptoms * Use of Cannabis (any form) outside of study as determined by urine drug screen a…
Interventions
- DrugCBD
Twice daily 100mg cannabidiol (CBD)
Location
- University of Wisconsin - MadisonMadison, Wisconsin